Submission of Certificate Under Reg. 74 (5) of SEBI (DP) Regulations, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted a compliance certificate to BSE from its Registrar and Share Transfer Agent (RTA), M/s Venture Capital and Corporate Investments Private Limited, for the quarter ended 31 December 2025. The certificate confirms that all physical share certificates received for dematerialisation were duly verified, mutilated, and cancelled, and that the names of NSDL and CDSL were updated as the registered owners within the 15-day SEBI-prescribed timeline. The certificate was signed by the RTA's authorised signatory and forwarded to BSE by Whole-time Director Venkateshwarlu Pulluru on 21 January 2026. The company, formerly known as Trimurthi Limited, has Scrip Code 536565 and ISIN INE314I01036.
This is a routine quarterly compliance disclosure with no material impact on shareholders or the stock price. It simply confirms that the RTA has processed share dematerialisation requests correctly and within SEBI's timelines.